Wu Pan-Feng, Tang Ju-yu, Li Kang-hua
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Tumour Biol. 2015 Feb;36(2):495-501. doi: 10.1007/s13277-015-3094-y. Epub 2015 Jan 25.
Giant cell tumor is a relatively uncommon but painful tumor of bone, which can metastasize to the lungs. The RANK pathway is often reported to be involved in the pathogenesis of giant cell tumor of bone (GCTB). This pathway is a key signaling pathway of bone remodeling that plays a critical role in differentiation of precursors into multinucleated osteoclasts, and activation of osteoclasts leading to bone resorption. Dysregulation of RANK ligand (RANKL)-RANK-osteoprotegerin (OPG) signaling cascade induces the imbalance between bone formation and bone resorption, which leads to the changes in bone mass, increases osteoclast-mediated bone destruction, bone metastasis, and the progression of existing skeletal tumors. Recent evidences have shown that targeting the components of RANKL-RANK-OPG signaling pathway is a promising approach in the treatment of GCTB. This review study has focused on the association of RANKL-RANK-OPG pathway in the pathogenesis and progression of GCTB as well as discussed the possible therapeutic strategies by targeting this pathway.
骨巨细胞瘤是一种相对罕见但会引起疼痛的骨肿瘤，可转移至肺部。RANK通路常被报道参与骨巨细胞瘤（GCTB）的发病机制。该通路是骨重塑的关键信号通路，在前体细胞分化为多核破骨细胞以及破骨细胞激活导致骨吸收过程中起关键作用。RANK配体（RANKL）-RANK-骨保护素（OPG）信号级联的失调会诱导骨形成与骨吸收之间的失衡，进而导致骨量变化、破骨细胞介导的骨破坏增加、骨转移以及现有骨肿瘤的进展。最近的证据表明，靶向RANKL-RANK-OPG信号通路的组成部分是治疗GCTB的一种有前景的方法。本综述研究聚焦于RANKL-RANK-OPG通路与GCTB发病机制及进展的关联，并讨论了靶向该通路的可能治疗策略。
